Stay updated on Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision: v3.4.3 was added and Revision: v3.4.2 was removed, indicating a software version update with no changes to the study details.
    Difference
    0.0%
    Check dated 2026-03-08T23:41:36.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    The change is a revision update from v3.4.1 to v3.4.2 with no impact on study content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-15T15:02:27.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Peking University People's Hospital was added as a study site in early 2026 after a prior removal in December 2025; the page revision also updated from v3.4.0 to v3.4.1.
    Difference
    0.1%
    Check dated 2026-02-08T11:25:47.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Adds a glossary toggle and makes small text/capitalization changes to metadata fields (e.g., Last Update statuses and No FEAR Act data). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-25T03:46:12.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    Revision tag updated from v3.3.3 to v3.3.4; no changes to the study details or page content were detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-18T01:53:34.000Z thumbnail image
  8. Check
    78 days ago
    Change Detected
    Summary
    Two new study sites were added: Chongqing, China (400042) and Thane, India (411107). The list also shows removal/rename of Yuzhong District (Chongqing 400042) and Thāne (411107).
    Difference
    0.1%
    Check dated 2025-12-27T18:25:44.000Z thumbnail image

Stay in the know with updates to Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.